Renowned pathologist and Joint Australian of the Year (2024) Professor Richard Schooler has died aged 59.
The scholar gained Australian and global attention when he volunteered to conduct the world’s first experimental treatment for brain cancer.
This not only prolonged his life span, but provided scientists with a wealth of information that can help shape the longer term of brain cancer treatment.
In an open letter Scolyer intended to be published when he died, he wrote:
“I sincerely hope that the scientific data and awareness I have generated will provide a platform for others to make a difference for future cancer patients.”
Richard Schooler is survived by his wife, Dr. Katie Nicholl, and their three children, Emily, Matt and Lucy.
Finding His Calling
Schooler grew up within the suburb of Riverside in Launceston, Tasmania. He described his memories of his childhood there as “mostly happy”, which he spent doing “all the normal things”, akin to biking and footy.
His family Used to go on beach vacations yearly, hung out swimming and playing cricket.
Scolyer was a lifelong sportsman, playing football as a youth, swimming, cycling, and running as an adult, and used his skills to lift funds for charity every time possible.
At ten years old, Schooler decided to develop into a health care provider, successfully finding his calling very early. He studied medicine on the University of Tasmania.
Once an authentic doctor, he excelled in his role, driven by immense compassion for his patients. His specialty was melanoma, and he was considered probably the greatest melanoma pathologists on this planet.
In 2017, Scholier was appointed Co-Medical Director of the Melanoma Institute of Australia, alongside her friend, colleague, and co-2024 Australian of the Year recipient, Professor Georgina Long.
Mich Tsikas/AAP
In mid-2023, Scolyer was diagnosed with advanced (stage 4) glioblastoma, essentially the most aggressive and customary type of brain cancer.
After diagnosis, Survival is often only around one year. Treatment for glioblastoma has remained largely unchanged in nearly 20 years, and frequently includes Chemotherapy, radiation therapy, and surgeryhowever the cancer almost all the time comes back.
However, knowing the severity of his disease, and the poor prognosis related to glioblastoma, Scolaire volunteered to undergo a brand new approach to glioblastoma treatment that borrowed from recent techniques within the melanoma space. These techniques are called immunotherapy.
Trailblazing cancer therapy
Immunotherapy is a term for a wide range of relatively recent techniques which might be becoming more widespread.
The immune system is remarkably strong. So strong, in truth, that it could hit almost anything, even you. Think of a severe allergic response – that is when the immune system is actually activated by mistake, and it could be life-threatening.
The immune system must be kept in check, and a method the body does that is by utilizing “checkpoints.” These are proteins on immune cells which might be like an “off switch” for the immune system.
It is smart, then, that one of the crucial widely used immunotherapies “Immune checkpoint inhibitorsThese are drugs that activate the immune system, “turning the off switch” to assist fight cancer.
To treat his glioblastoma, Scholer was given. Simultaneous doses Three different checkpoint inhibitors, followed 12 days later by surgery to remove as much cancer as possible from his brain.
Scolyer then underwent six weeks of radiation therapy, received some additional checkpoint inhibitors, and even a “personal peptide vaccination.”
Peptide vaccination is one other sort of immunotherapy. The goal is to attempt to teach the immune system what a patient’s cancer cells appear like, so the immune system can higher fight against them if their cancer comes back.
Eighteen months after surgery, Scholar’s tumor still hadn’t gone away.
A disease like glioblastoma was difficult to treat, it was an incredible result, and a testament to the skill of the scientists and physicians involved, in addition to the tenacity and strength of Schooler himself.
The success of his treatment soon led to Designing a clinical trialLooking at how this recent glioblastoma treatment program might be adapted and used more widely in the longer term.
Schooler’s bravery and trailblazing approach to self-care will almost definitely help extend the lives of lots of, if not hundreds, of people that might be diagnosed with glioblastoma in the longer term.
Furthermore, researchers will give you the option to adapt these techniques to treat other cancers and diseases, with the potential to profit much more patients.
A remarkable expansion
Sadly, in March 2025, Schooler announced that her cancer had returned. It had been almost two years since his original diagnosis – a remarkable extension of his life given the harmful nature of his disease.
Scolyer will survive within the memories of all who knew him, and his contributions to science and medicine will touch the lives of individuals around the globe for years to return, even in the event that they never knew his name.